Clinical Trial

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-06-07; most recent amendment 2026-07-07.
Status change: Not Yet Recruiting → Recruiting 2022-06-15
Trial Details
NCT Number NCT05413421
Lead Sponsor ORIC Pharmaceuticals
Conditions Metastatic Prostate Cancer
Enrollment 275 participants
Start Date 2022-06-01
Primary Completion 2027-06 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-09